(BMEZ) BlackRock Health Sciences - Overview
Sector: Financial Services | Industry: Asset Management | Exchange: NYSE (USA) | Market Cap: 898m USD | Total Return: 17.3% in 12m
Total Rating 44
Safety 70
Buy Signal 0.65
Asset Management
Industry Rotation: +3.7
Industry Rotation: +3.7
Market Cap:
898M
Avg Turnover: 3.39M USD
Avg Turnover: 3.39M USD
ATR:
1.65%
Peers RS (IBD): 55.0
Peers RS (IBD): 55.0
Risk 5d forecast
Volatility16.6%
Rel. Tail Risk-2.81%
Reward TTM
Sharpe Ratio0.89
Alpha-1.33
Character TTM
Beta0.653
Beta Downside0.694
Drawdowns 3y
Max DD18.41%
CAGR/Max DD0.41
EPS (Earnings per Share)
EPS CAGR: 60.44%
EPS Trend: -2.0%
EPS Trend: -2.0%
Qual. Beats: 0
Revenue
Rev. CAGR: 67.56%
Rev. Trend: -17.9%
Rev. Trend: -17.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: BMEZ BlackRock Health Sciences
Piotroski VR‑10 (Strict)
6.0
| Net Income: 43.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.79 > 1.0 |
| NWC/Revenue: 44.75% < 20% (prev 24.88%; Δ 19.86% < -1%) |
| CFO/TA 0.09 > 3% & CFO 70.3m > Net Income 43.5m |
| Net Debt (-26.3m) to EBITDA (43.5m): -0.60 < 3 |
| Current Ratio: 153.7 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (13.3m) vs prev -4.94% < -2% |
| Gross Margin: 89.79% > 18% (prev 3.52%; Δ 8.63k% > 0.5%) |
| Asset Turnover: 8.54% > 50% (prev 1.35%; Δ 7.19% > 0%) |
| Interest Coverage Ratio: -100.0k > 6 (EBITDA TTM 43.5m / Interest Expense TTM 78.0) |
Altman Z''
10.00
| A: 0.03 (Total Current Assets 26.6m - Total Current Liabilities 173k) / Total Assets 774.6m |
| B: -0.22 (Retained Earnings -173.5m / Total Assets 774.6m) |
| C: -0.03 (EBIT TTM -21.5m / Avg Total Assets 690.4m) |
| D: 129.5 (Book Value of Equity 768.6m / Total Liabilities 5.93m) |
| Altman-Z'' Score: 135.3 = AAA |
What is the price of BMEZ shares?
As of April 16, 2026, the stock is trading at USD 14.77 with a total of 243,528 shares traded.
Over the past week, the price has changed by +2.29%, over one month by +4.75%, over three months by -2.11% and over the past year by +17.25%.
Over the past week, the price has changed by +2.29%, over one month by +4.75%, over three months by -2.11% and over the past year by +17.25%.
Is BMEZ a buy, sell or hold?
BlackRock Health Sciences has no consensus analysts rating.
What are the forecasts/targets for the BMEZ price?
| Analysts Target Price | - | - |
BlackRock Health Sciences (BMEZ) - Fundamental Data Overview
as of 14 April 2026
P/E Trailing = 5.6575 P/S = 8.8416
P/B = 0.8403
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278k USD (from shortTermDebt, last quarter)
Debt = 278k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (recalculated: Debt 278k - CCE 26.6m)
Enterprise Value = 871.9m USD (898.1m + Debt 278k - CCE 26.6m)
Interest Coverage Ratio = -276k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
EV/FCF = 12.40x (Enterprise Value 871.9m / FCF TTM 70.3m)
FCF Yield = 8.06% (FCF TTM 70.3m / Enterprise Value 871.9m)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.13 (Enterprise Value 871.9m / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 173k)
Debt / Equity = 0.00 (Debt 278k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.60 (Net Debt -26.3m / EBITDA 43.5m)
Debt / FCF = -0.37 (Net Debt -26.3m / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.30% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.3m)
WACC = 8.28% (E(898.1m)/V(898.4m) * Re(8.28%) + D(278k)/V(898.4m) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF] Terminal Value 80.69% ; FCFF base≈55.0m ; Y1≈67.8m ; Y5≈115.7m
[DCF] Fair Price = 30.51 (EV 1.88b - Net Debt -26.3m = Equity 1.91b / Shares 62.5m; r=8.28% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -2.05 | EPS CAGR: 60.44% | SUE: N/A | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0
External Resources